metadata toggle
Clinical particulars
Target species
Pigs (sows and gilts).
Indications for use
For the passive immunisation of piglets by active immunisation of sows/gilts to reduce mortality and clinical signs such as diarrhoea due to neonatal enterotoxicosis during the first days of life, caused by those E.coli strains, which express the fimbrial adhesins F4ab (K88ab), F4ac (K88ac), F5 (K99) or F6 (987P).
Contraindications
None.
Special warnings for each target species
None.
Special precautions for use
Before using the vaccine allow it to reach room temperature (15 - 25 °C) and shake well before use.
Use sterile syringes and needles.
Avoid introduction of contamination.
Vaccinate only healthy animals.
Operator warnings
In the case of accidental self-injection, seek medical advice immediately and show the package leaflet or label to the physician.
Adverse reactions
A mean transient increase in body temperature of about 1°C, in some pigs up to 3°C, may occur in the first 24 hours after vaccination. Reduced feed intake and listlessness may occur in approximately 10% of the animals on the day of vaccination, but returns to normal within 1 - 3 days. A transient swelling and redness at the injection site may be observed in approximately 5% of the animals. The diameter of the swelling is in general below 5 cm, but in some cases a larger swelling may occur. Swelling and redness at the injection site may occasionally last for at least 14 days.
Use during pregnancy or lactation
The vaccine can be used during pregnancy.
Interactions
No information is available on the safety and efficacy from concurrent use of this vaccine with any other. It is therefore recommended that no other vaccine should be administered within 14 days before or after vaccination with this product.
Amounts to be administered and administration route
Intramuscular injection in sows/gilts of 2 ml of the vaccine per animal in the neck in the area behind the ear.
Vaccination scheme:
Basic vaccination: Sows/gilts which have not yet been vaccinated with the product shall be given an injection preferably 6 to 8 weeks before the expected date of farrowing followed by a second injection 4 weeks later.
Revaccination: A single revaccination shall be carried out during the second half of each subsequent pregnancy, preferably 2 to 4 weeks before the expected date of farrowing.
Overdose
No undesirable effects other than those observed and mentioned in the “Adverse reactions” section have been observed.
Withdrawal period
Zero days.